Management of chronic spontaneous urticaria in real life - In accordance with the guidelines? A cross-sectional physician-based survey study

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 1, 2013, Pages 43-50

  Weller, K ^a   Viehmann, K ^b   Brautigam M ^c   Krause, K ^a   Siebenhaar, F ^a   Zuberbier, T ^a   Maurer, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Institute of Empirical Health Economics   (Germany)

^c Novartis Pharma   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; DAPSONE; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENT; OMALIZUMAB; STEROID;

ADULT; ARTICLE; CHRONIC SPONTANEOUS URTICARIA; CROSS-SECTIONAL STUDY; FEMALE; GENERAL PRACTITIONER; GERMANY; HEALTH SURVEY; HUMAN; MALE; PHYSICIAN; PRACTICE GUIDELINE; PRICK TEST; PRIORITY JOURNAL; PRIVATE PRACTICE; QUESTIONNAIRE; SKIN TEST; URTICARIA;

ADULT; ATTITUDE OF HEALTH PERSONNEL; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DERMATOLOGY; FEMALE; GERMANY; GUIDELINE ADHERENCE; HISTAMINE ANTAGONISTS; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE; QUESTIONNAIRES; STATISTICS, NONPARAMETRIC; STEROIDS; URTICARIA;

EID: 84872872407     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04370.x     Document Type: Article

References (31)

1. Maurer M, Ortonne J, Zuberbier T,. Chronic urticaria: a patient survey on quality-of-life, treatment usage and doctor-patient relation. Allergy 2009; 64: 581-588.
2. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427-1443.
3. Greaves MW,. Chronic urticaria. N Engl J Med 1995; 332: 1767-1772.
4. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1417-1426.
5. 2LEN task force report. Allergy 2011; 66: 317-330.
6. Weldon D,. Quality of life in patients with urticaria. Allergy Asthma Proc 2006; 27: 96-99.
7. Grob J, Revuz J, Ortonne J, Auquier P, Lorette G,. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005; 152: 289-295.
8. Młynek A, Magerl M, Hanna M, et al. The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy 2009; 64: 927-936.
9. Lewis V, Finlay A,. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9: 169-180.
10. O'Donnell B, Lawlor F, Simpson J, Morgan M, Greaves M,. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136: 197-201.
11. Kapp A, Demarteau N,. Cost effectiveness of levocetirizine in chronic idiopathic urticaria: a pooled analysis of two randomised controlled trials. Clin Drug Investig 2006; 26: 1-11.
12. Delong L, Culler S, Saini S, Beck L, Chen S,. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol 2008; 144: 35-39.
13. Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006; 61: 321-331.
14. Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006; 61: 316-320.
15. Weller K, Viehmann K, Bräutigam M, et al. Cost intensive, time consuming, problematical?-How physicians in the practice setting experience care of urticaria patients. J Dtsch Dermatol Ges 2011; Nov 23. doi: 10.1111/j.1610-0387.2011.07822.x [Epub ahead of print].
16. Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M,. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol 2010; 35: 869-873.
17. Maurer M, Metz M, Magerl M, Siebenhaar F, Staubach P,. Autoreactive urticaria and autoimmune urticaria. Hautarzt 2004; 55: 350-356.
18. Weller K, Schoepke N, Krause K, Ardelean E, Bräutigam M, Maurer M,. Selected urticaria patients benefit from a referral to tertiary care centers-results of an expert survey. J Eur Acad Dermatol Venereol 2011; DOI: 10.1111/j.1468-3083.2011.04387.x.
19. Kozel MM, Bossuyt PM, Mekkes JR, Bos JD,. Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: a systematic review. J Am Acad Dermatol 2003; 48: 409-416.
20. Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 2010; 65: 459-466.
21. Staevska M, Popov T, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010; 125: 676-682.
22. Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M,. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009; 123: 672-679.
23. Giménez-Arnau A, Izquierdo I, Maurer M,. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol 2009; 23: 1088-1091.
24. Engin B, Ozdemir M,. Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2008; 22: 481-486.
25. Kozel MM, Sabroe RA,. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004; 64: 2515-2536.
26. Vena G, Cassano N, Colombo D, Peruzzi E, Pigatto P, Group N-I-S,. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006; 55: 705-709.
27. Kessel A, Toubi E,. Cyclosporine-A in severe chronic urticaria: the option for long-term therapy. Allergy 2010; 65: 1478-1482.
28. Kaplan A, Joseph K, Maykut R, Geba G, Zeldin R,. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008; 122: 569-573.
29. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011; 128: 202-209.
30. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011; 128: 567-573 e561.
31. Metz M, Altrichter S, Ardelean E, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2010; 154: 177-180.